title: [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
abstract: Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily practice based on interdisciplinary co-operation between urology and nuclear medicine. Ra-223 has been approved under the product name Xofigo® by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
authors.affiliation: Prostatakrebszentrum, Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland, heinzer@martini-klinik.de.
authors.forename: H
authors.initials: H
authors.lastname: Heinzer
authors.forename: F
authors.initials: F
authors.lastname: König
authors.forename: S
authors.initials: S
authors.lastname: Klutmann
mesh_terms: D000512:Alpha Particles / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D002986:Clinical Trials as Topic; D003299:Cooperative Behavior; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D033183:Interdisciplinary Communication; D008297:Male; D010166:Palliative Care / Q000379:methods; D064129:Prostatic Neoplasms, Castration-Resistant / Q000401:mortality / Q000532:radiotherapy*; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D011883:Radium / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D011868:Radioisotopes; C581106:radium Ra 223 dichloride; D011883:Radium